Barclays Downgrades Ortho Clinical Diagnostic to Equal-Weight, Lowers Price Target to $25
Author: Benzinga Newsdesk | December 27, 2021 05:12am
Barclays analyst Luke Sergott downgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from Overweight to Equal-Weight and lowers the price target from $29 to $25.